A single DEX/CRH test in male drug-free depressed patients is associated with the clinical response to treatment with fluoxetine

Journal of Psychiatric Research

Volumn 44, Issue 16, 2010, Pages 1154-1157

  Paslakis, Georgios ^a   Heuser, Isabella ^a,b,c   Schweiger, Ulrich ^c,d   Deuschle, Michael ^a,c  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; DEXAMETHASONE; FLUOXETINE; HYDROCORTISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; HORMONE RESPONSE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MALE; MELANCHOLIA; MENTAL PATIENT; PRIORITY JOURNAL; PROVOCATION TEST; PSYCHOPHARMACOTHERAPY; TREATMENT RESPONSE;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AREA UNDER CURVE; CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; DEXAMETHASONE; FLUOXETINE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS;

EID: 78649982158     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2010.04.010     Document Type: Article

References (21)

1. Araya A.V., Rojas P., Fritsch R., Rojas R., Herrera L., Rojas G., Gatica H., Silva H., Fiedler J.L. Early response to venlafaxine antidepressant correlates with lower ACTH levels prior to pharmacological treatment. Endocrine 2006, 30(3):289-298.
2. Binder E.B., Künzel H.E., Nickel T., Kern N., Pfennig A., Majer M., Uhr M., Ising M., Holsboer F. HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients. Psychoneuroendocrinology 2009, 34:99-109.
3. Brouwer J.P., Appelhof B.C., van Rossum E.F.C., Koper J.W., Fliers E., Huyser J., Schene A.H., Tijssen J.G.P., Van Dyck R., Lamberts S.W.J., Wiersinga W.M., Hoogendijk W.J.G. Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. Psychoneuroendocrinology 2006, 31:1154-1163.
4. Deuschle M., Schmider J., Weber B., Standhardt H., Korner A., Lammers C.H., Schweiger U., Hartmann A., Heuser I. Pulse-dosing and conventional application of doxepin: effects on psychopathology and hypothalamus-pituitary adrenal (HPA) system. Journal of Clinical Psychopharmacology 1997, 17:156-160.
5. Frieboes R.M., Sonntag A., Yassouridis A., Eap C.B., Baumann P., Steiger A. Clinical outcome after trimipramine in patients with delusional depression - a pilot study. Pharmacopsychiatry 2003, 36:12-17.
6. Hatzinger M., Hemmeter U.M., Baumann K., Brand S., Holsboer-Trachsler E. The combined DEX-CRH test in treatment course and long-term outcome of major depression. Journal of Psychiatric Research 2002, 36:287-297.
7. Heuser I., Yassouridis A., Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J.Psychiatr.Res. 1994, 28:341-356.
8. Heuser I.J., Schweiger U., Gotthardt U., Schmider J., Lammers C.H., Dettling M., Yassouridis A., Holsboer F. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. American Journal of Psychiatry 1996, 153:93-99.
9. Horstmann S., Dose T., Lucae S., Kloiber S., Menke A., Hennings J., Spieler D., Uhr M., Holsboer F., Ising M. Suppressive effect of mirtazapine on the HPA system in acutely depressed women seems to be transient and not related to antidepressant action. Psychoneuroendocrinology 2009, 34(2):238-248.
10. Ising M., Künzel H.E., Binder E.B., Nickel T., Modell S., Holsboer F. The combined dexamethasone/CRH test as a potential surrogate marker in depression. Progress in Neuro-psychopharmacology and Biological Psychiatry 2005, 29:1085-1093.
11. Ising M., Horstmann S., Kloiber S., Lucae S., Binder E.B., Kern N., Kunzel H.E., Pfennig A., Uhr M., Holsboer F. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker?. Biological Psychiatry 2007, 62:47-54.
12. Künzel H.E., Ackl N., Hatzinger M., Held K., Holsboer-Trachsler E., Ising M., Kaschka W., Kasper S., Konstantinidis A., Sonntag A., Uhr M., Yassouridis A., Holsboer F., Steiger A. Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol-a double-blind multicenter trial. Journal of Psychiatric Research 2009, 43(7):702-710.
13. Kunugi H., Ida I., Owashi T., Kimura M., Inoue Y., Nakagawa S., Yabana T., Urushibara T., Kanai R., Aihara M., Yuuki N., Otsubo T., Oshima A., Kudo K., Inoue T., Kitaichi Y., Shirakawa O., Isogawa K., Nagayama H., Kamijima K., Nanko S., Kanba S., Higuchi T., Mikuni M. Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a multicenter study. Neuropsychopharmacology 2006, 31:212-220.
14. Nickel T., Sonntag A., Schill J., Zobel A.W., Ackl N., Brunnauer A., Murck H., Ising M., Yassouridis A., Steiger A., Zihl J., Holsboer F. Clinical and neurobiological effects of tianeptine and paroxetine in major depression. Journal of Clinical Psychopharmacology 2003, 23:155-168.
15. Nikisch G., Mathe A.A., Czernik A., Thiele J., Bohner J., Eap C.B., Agren H., Baumann P. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology (Berl) 2005, 181:751-760.
16. Scharnholz B, Hamann B, Lederbogen F, Schilling C, Gilles M, Onken V, Frankhauser P, Kopf D, Deuschle M. Antidepressive treatment with mirtazapine, but not venlafaxine lowers cortisol concentrations in saliva: a randomised open trial. Psychiatry Research, in press.
17. Schüle C., Baghai T.C., Eser D., Häfner S., Born C., Herrmann S., Rupprecht R. The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression. PLoSOne 2009, 4(1):e4324.
18. Schüle C., Baghai T.C., Eser D., Zwanzger P., Jordan M., et al. Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients. Psychopharmacology (Berl) 2006, 186:601-611.
19. Schüle C., Baghai T., Zwanzger P., Ella R., Eser D., Padberg F., Moller H.J., Rupprecht R. Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine. Psychopharmacology (Berl) 2003, 166:271-275.
20. Watson S., Gallagher P., Del-Estal D., Hearn A., Ferrier I.N., Young A.H. Hypothalamic- pituitary-adrenal axis function in patients with chronic depression. Psychological Medicine 2002, 32:1021-1028.
21. Zobel A.W., Nickel T., Sonntag A., Uhr M., Holsboer F., Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. Psychiatry Research 2001, 35:83-94.